
Bristol Myers Squibb Gains EU Approval to Expand Breyanzi CAR T Therapy for Follicular Lymphoma
Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or …